ZyVersa Therapeutics, Inc. (ZVSA)
NASDAQ: ZVSA · Real-Time Price · USD
0.995
-0.035 (-3.40%)
Dec 3, 2024, 1:44 PM EST - Market open
ZyVersa Therapeutics Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
| TTM
| FY 2023 | FY 2022 | FY 2021 | FY 2020 |
| Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
| Selling, General & Admin | 7.71 | 11.21 | 8.03 | 5.58 | 5.36 |
| Research & Development | 1.92 | 3.21 | 5.81 | 2.12 | 6.47 |
| Operating Expenses | 9.63 | 14.42 | 13.83 | 7.7 | 11.83 |
| Operating Income | -9.63 | -14.42 | -13.83 | -7.7 | -11.83 |
| Interest Expense | -0.13 | - | -0.43 | -0.82 | -0.52 |
| Interest & Investment Income | - | 0 | - | - | - |
| Other Non Operating Income (Expenses) | - | - | -0.61 | 0.23 | -0.33 |
| EBT Excluding Unusual Items | -9.76 | -14.42 | -14.87 | -8.3 | -12.68 |
| Impairment of Goodwill | - | -11.9 | - | - | - |
| Other Unusual Items | - | - | - | 0.21 | - |
| Pretax Income | -21.92 | -107.75 | -14.87 | -8.08 | -12.68 |
| Income Tax Expense | -0.59 | -9.46 | -0.75 | - | - |
| Net Income | -21.33 | -98.3 | -14.12 | -8.08 | -12.68 |
| Preferred Dividends & Other Adjustments | - | 7.95 | - | - | - |
| Net Income to Common | -21.33 | -106.25 | -14.12 | -8.08 | -12.68 |
| Shares Outstanding (Basic) | 1 | 0 | 23 | 2 | 0 |
| Shares Outstanding (Diluted) | 1 | 0 | 23 | 2 | 0 |
| Shares Change (YoY) | -97.10% | -99.57% | 849.06% | 3478.59% | - |
| EPS (Basic) | -32.03 | -1089.70 | -0.62 | -3.35 | -187.81 |
| EPS (Diluted) | -32.03 | -1089.70 | -0.62 | -3.35 | -187.81 |
| Free Cash Flow | -9.12 | -8.72 | -4.89 | -5.08 | -5.11 |
| Free Cash Flow Per Share | -13.70 | -89.44 | -0.21 | -2.10 | -75.66 |
| EBITDA | -9.62 | -14.41 | -13.82 | -7.69 | -11.82 |
| D&A For EBITDA | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
| EBIT | -9.63 | -14.42 | -13.83 | -7.7 | -11.83 |
Source: S&P Capital IQ. Standard template.
Financial Sources.